131 related articles for article (PubMed ID: 26069178)
1. Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study.
Sadighi S; Keyhani A; Harirchi I; Garajei A; Aghili M; Kazemian A; Motiee Langroudi M; Zendehdel K; Nikparto N
Acta Med Iran; 2015; 53(6):380-6. PubMed ID: 26069178
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
3. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M
Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
Chang PM; Lu HJ; Wang LW; Tai SK; Chen MH; Chu PY; Yang MH
Head Neck; 2017 Jul; 39(7):1333-1342. PubMed ID: 28370774
[TBL] [Abstract][Full Text] [Related]
7. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
13. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Paccagnella A; Mastromauro C; D'Amanzo P; Ghi MG
Oncologist; 2010; 15 Suppl 3():8-12. PubMed ID: 21036883
[TBL] [Abstract][Full Text] [Related]
18. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
[TBL] [Abstract][Full Text] [Related]
19. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
